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Chronic prostatitis (CP) is a chronic inflammation in the prostate with unsatisfactory management. Danggui Beimu Kushen Wan
(DBKW) is a classic formula developed 1800 years ago for patients with difficult urination and it has been widely utilized for CP
in modern days. However, scientific understanding of DBKW on CP has not been systematically reviewed. First, we searched the
Encyclopedia of Traditional ChineseMedicine for the etiologies and pathogeneses of CP-like symptoms and DBKW and compared
their similarities and differences from traditional Chinese medicine and conventional medicine perspectives. Then, we searched
21 electronic databases to identify potential clinical and experimental studies. Characteristics of included studies, ingredients,
herb frequency, and possible mechanisms of actions were descriptively summarized. Risk of bias of randomized controlled trials
(RCTs) was evaluated using the Cochrane risk of bias assessment tool. A total of 290 studies were identified. Six clinical studies,
including four RCTs and two case series, and eight experimental studies were included. Clinical studies indicated that DBKW used
alone or as an adjunct therapy significantly reduced the CP symptom scores and decreased the expressed prostatic secretions-
pH when compared to antibiotics or 𝛼-blocker. Most RCTs have high or unclear risk of bias. Experimental studies revealed
that DBKW may have effects on anti-inflammation, antibacteria, antioxidation, sex hormone regulation, and immunoregulation.
DBKW demonstrated a great potential in the treatment of CP. High-quality RCTs and network pharmacological studies should be
considered for future research.
1. Introduction
Prostatitis is a common inflammatory prostate disorder that
affects approximately 30% to 50% of men [1, 2]. A systematic
review involving more than 10,000 patients claimed that
the prevalence of prostatitis symptoms is around 8.2% [1].
Men aged 36 to 50 years seem to be prone to have this
condition although it impacts men of all ages [3]. The
National Institute of Health of United States (NIH) defines
the chronic types of prostatitis as chronic bacterial prostatitis
(CBP) and chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS) [4]. Urogenital pain, sexual dysfunction, psycho-
logical symptoms, and lower urinary tract symptoms (i.e.,
frequent, urgent, and painful micturition) are the primary
chronic prostatitis-related symptoms [5]. Conventional man-
agement for CBP and CP/CPPS includes medications (i.e.,
antibiotics, 𝛼-blocker, anti-inflammatory, and 5𝛼-reductase-
inhibitors), surgery, physiotherapies, and psychotherapies
[6, 7]. Recurrences are common when patients stop using
medications [8]. A study which enrolled 68,675 patients
pointed out that menwho suffered fromCP had a 30%higher
probability of developing prostate cancer (PCa) than others
[9]. However, the treatment effects of current management
are unsatisfactory.
There is a trend to identify potential treatment from
traditional knowledge to guide modern drug discovery [10].
In antiquity, terminologies for prostate or prostate disorders
(such as CP, CBP, and CPPS) did not exist. However, relevant
records can be found to describe prostatitis-related symptoms
such as Jing Zhuo in traditional Chinese medicine (TCM)
[11], with applications of various herbal formulas [12–14].
Within all records of formulas, Danggui Beimu Kushen Wan
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(Chinese Angelica, Fritillaria and Flavescent Sophora Pill;
DBKW) is one of the formulas that are indicated for difficult
urination in pregnantwomen ormale patients. In themodern
era, this formula has been widely utilized for a range of
prostate disorders involving CP [15], benign prostatic hyper-
plasia [16], and PCa [17]. This formula containing Angelicae
Sinensis Radix (Dang gui), Fritillariaeunbergii Bulbus (Zhe
bei mu), Sophorae Flavescentis Radix (Ku shen), and Talcum
(Hua shi) was initially created by ZHANG Zhong-jing (150-
219AD), theChinesemedical sage, detailed in JinGuiYaoLue
(Synopsis of Prescriptions of the Golden Chamber; JGYL),
approximately 1800 years ago [18]. However, its applications
have not been systematically reviewed. This study aimed to
systematically review the existing clinical and experimental
studies of DBKW.
2. Pathophysiology of CP in TCM and
Conventional Medicine
We searched Zhong Hua Yi Dian (Encyclopedia of Tradi-
tional Chinese Medicine; ZHYD), a CD-ROM containing
1,156 ancient books, to identify potential classic literature of
Jing Zhuo andDBKW [11].The original record of “Jing Zhuo”
in TCM could be traced back to Mi Chuan Zheng Zhi Yao
Jue (Essentials for Esoteric Treatment; DAI Yuan-li; 1443)
and it was caused by stagnation in water passage. Then a
series of classic literature also documented its etiologies and
pathogeneses in different aspects. Ben Cao Pin Hui Jing Yao
(Collected Essentials of Species ofMateriaMedica; LIUWen-
tai; 1505) described the systems of Jing Zhuomainly presented
in difficult urination with white discharge in urinary meatus,
due to hyperactivity of fire or yin deficiency. Wang Xu Gao
Lin Zheng Yi An (Wang Xugao’s Clinical Cases; WANG Xu-
gao; 1897) believed that it resulted from external dampness
and heat while Mei Shou Tang Fang An Xuan Cun (Mei Shou
Tang’s Selected Cases; YE Tian-shi; n.d) thought internal
dampness and heat led to Jing Zhuo. In addition, Zang
deficiency described in Yi Xue Ru Men (Introduction to
Medicine; LI Ting; 1575), high frequency of sexual intercourse
documented in Fu Xi Mi Chuan Jian Yan Fang (Fu Xi’s
Esoteric Experienced Formulae; LU Jin-sui; 1918), and Liver-
qi stagnation recorded inMai Jian Bu Yi (Annotation of Pulse
Diagnosis; ZHOUXue-hai; 1892)were the other three reasons
that caused Jing Zhuo. Figure 1 shows the common etiologies
and pathogeneses of Jing Zhuo in TCM based on the
description in the textbook of Surgery of Chinese Medicine
[19]. On the other hand, although the exact pathophysiology
of CP is unknown, five primary hypotheses were proposed
in modern research, including prostate pathogen infection
[20, 21], intraprostatic urinary reflux [22–24], oxidative stress
[25–27], abnormal sex hormone level [28–31], and abnormal
immunoreaction [27, 32–34]. Detailed pathophysiology of
prostatitis in conventional medicine and the relationship
between TCM and conventional medicine are illustrated in
Figure 1.
Compared to the etiologies and pathogeneses of Jing
Zhuo recorded in classic literature, it is not difficult to find
that there are some similarities in TCM and conventional
medicine. TCMbelieves that all pathogens causing infections,
such as viruses, bacteria, fungi, mycoplasma, and chlamydia
belong to the category of external pathogenic factors, whereas
internal dampness may be produced when the urinary reflux
exists, according to the intraprostatic urinary reflux hypoth-
esis [35]. Recent research has shown that oxidative stress
may be relevant to emotional stress (i.e., excessive rage or
depression) [36, 37] or irregular lifestyle [38]. Moreover, the
frequency of sexual intercourse and sex hormone level may
have a certain connection with each other [39] that could also
be considered to belong to the category of irregular lifestyle
in TCM or conventional theories, causing the development
of CP [40]. Patients who are elderly or constitutionally weak
may be more prone to abnormal immunoreaction that may
lead to CP [41]. Based on the above findings, both TCM
and conventional medicine have their own understanding
of prostatitis. However, it is essential to be aware that
these etiologies and pathogeneses arrive at the same end by
different means.
In JGYL, DBKW was documented to treat difficult
urination [18]. Some classic TCM literature recorded its
pathogenesis [11]. For example, Chang Sha Yao Jie (Changsha
Explanation of Medicines; HUANG Yuan-yu; 1753) and
Jin Gui Xuan Jie (Explanation to the Synopsis of Golden
Chamber; HUANG Yuan-yu; 1754) recorded that abnormal
bladder Qi-Hua was one of the pathogeneses that cause
difficult urination. The other one was heat stagnation in
Lower-Jiao, which could be detected in Jin Gui Yao Lue
Guang Zhu (Extensive Commentary to the Treatise on the
Synopsis of Prescriptions of the Golden Chamber; LI Wen;
1682), Tai Chan Xin Fa (Experience in Obstetrics; Yan Chun-
xi; 1730), and Nu Ke Yao Zhi (Essential Guide of Gynecology,
CHEN Nian-zu; 1804). Moreover, Lin Zheng Zhi Nan Yi
An (Case Records as a Guide to Clinical Practice; LZZNYA;
YE Tian-shi; 1746) distinctly pointed out that the primary
rule of treatment for Jing Zhuo was clearing dampness and
heat. Compared to the description in LZZNYA as well as the
pathogeneses of CP listed in Figure 1, these two pathogeneses
of DBKW partially overlap and match the pathogeneses of
prostatitis.
3. Modern Scientific Exploration of
DBKW on CP
We searched the following 21 electronic bibliographic English
and Chinese databases from their respective inception to
17 April 2018 to identify potential clinical and experimental
studies, including the Cochrane Central Register of Con-
trolled Trials, PubMed, EMBASE, CINAHL, Informit, Sci-
ence Direct, LILACS (Latin American and Caribbean Health
Sciences), ProQuest, AMED, Blackwell Synergy, PsycINFO,
INDMED, AcuBriefs, Ingenta, Koreamed, ERIC, mRCT,
CNKI, CQVIP, Wanfangdata, and CBM. Keywords used to
identify clinical studies included Danggui Beimu Kushen
Wan, clinical studies, clinical trials, case reports, and their
synonyms. Keywords used to identify experimental studies
included Danggui Beimu KushenWan, experimental studies,
in vivo, in vitro, and their synonyms. A manual search was
performed to screen the reference list of review articles for
potential studies.
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Figure 1: Etiologies and pathogeneses of chronic prostatitis in traditional Chinesemedicine and conventionalmedicine and their relationship.
For clinical studies, all types of clinical studies (e.g.,
RCTs and case series), published in English or Chinese,
were considered, regardless of the type of publication. The
studies were included if they focused on CP using DBKW or
modified DBKW as the intervention. For controlled studies,
the control group can be a conventional medicine, placebo or
no treatment. The literature was excluded if the participants
were not suffering from CP, or the formula used in the study
was not modified from DBKW, or diagnosis of CP was not
provided, or an inappropriate control group was involved.
The experimental studies (e.g., animal studies, in vivo, in
vitro) related to the mechanisms of action of DBKW for the
management of CPwere included in the review.The literature
was excluded if the studies were not for CP.
One reviewer (HL) screened the included clinical and
experimental studies and extracted the following data to
two predesigned Excel spreadsheet templates: (1) study type,
sample size, dropouts, diagnosis, interventions, duration,
outcome measurement, adverse events, follow-up, and herb
ingredients for clinical studies; (2) animal types, sample size,
diagnosis, interventions, duration, outcome measurement,
and herb ingredients for experimental studies. Risk of bias
of the included RCTs was assessed by one reviewer (HL)
with the Cochrane risk of bias assessment tool [42] as
well. The second reviewer (AY) checked and confirmed the
data and assessment process. Any discrepancies between the
two reviewers were resolved through discussion with the
third party (AH). Characteristics of included clinical and
experimental studies, herb ingredients, herb frequency, study
results, and possible pharmaceutical effectswere descriptively
summarized.
A total of 290 clinical and experimental studies were
identified following the search strategies outlined above.
Six clinical studies and eight experimental studies meeting
the inclusion criteria were included in the review. Figure 2
illustrates the detailed selection process.
3.1. Overall Clinical Implications of DBKW on CP. Six clinical
studies were included in the review, involving four RCTs [12,
15, 43, 44] and two case series [45, 46]. Characteristics of six
identified clinical studies were summarized in Table 1.
Among six included studies, one RCT focused on the
treatment of CBP [15], one RCT [12] and one case series
[45] for CP/CPPS, two studies for both CBP and CP/CPPS
(one RCT [43] and one case series [46]), and one RCT for
CP without any specified category [44]. In terms of herbal
intervention, five studies applied modified DBKW decoction
as an intervention [15, 43–46] and the other one utilized
original DBKW decoction [12]. Three RCTs compared mod-
ified DBKW with western drugs [15, 43, 44] and one RCT
compared original DBKW plus 𝛼-blocker with the same 𝛼-
blocker only [12]. Details of herb ingredients in the included
clinical studies are presented in Table 2.
There are a total 19 herbs used in basic prescriptions
in the included studies and eight herbs were utilized more
than once, including Angelicae Sinensis Radix (Dang gui; six
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Figure 2: Flowchart of the selection process for identifying studies to be included in the review.
times), Fritillariaeunbergii Bulbus (Zhe bei mu; six times),
Sophorae Flavescentis Radix (Ku shen; six times), Talcum
(Hua shi; five times), Vaccariae Semen (Wang bu liu xing;
twice), Phellodendri Chinensis Cortex (Huang bai; twice),
Taraxaci Herba (Pu gong ying; twice), and Cyathulae Radix
(Chuan niu xi; twice). These herbs are from heat-clearing,
blood-invigorating and blood stasis-removing, and tonifying
categories. Due to the significant variety of herbs used in
the included studies, it is infeasible to assess the effects of
the basic formula (i.e., DBKW) across different studies. It
is recommended that future research considers using the
formula with original ingredients to ensure the possibility of
data synthesis.
None of the included RCTs involved placebo or any treat-
ment in the control group. All of them utilized conventional
medicines (antibiotic or 𝛼-blocker drugs) as the comparators
[12, 15, 43, 44]. Both Guo [43] and Wu [15] claimed that
the total effectiveness rate of modified DBKW was superior
to antibiotic drugs; however, detailed data are not available
for further synthesis. Another RCT comparing DBKW with
ofloxacin indicated that DBKW could significantly decrease
pH level in the expressed prostatic secretions test (EPS)
(mean difference (MD) -0.17, 95% confidence interval (CI) -
0.33 to -0.01) [44]. Although Wu [44] claimed that statistical
significance existed in the improvement rate of EPS-white
blood cell counts between DBKW and ofloxacin, the effect
size analysis did not support this finding (odds ratio (OR)
1.72, 95% CI 0.63 to 4.72) and neither did the EPS-lecithin
body between DBKW and ofloxacin (MD -0.02, 95% CI -
0.32 to 0.28). Furthermore, the trial from Zhang, Yang, and
Chen revealed that the adjunct effects of basic DBKWdecoc-
tion were superior to terazosin hydrochloride, evidenced
by reducing the score of NIH-Chronic Prostatitis Symptom
Index (NIH-CPSI) (MD -3.08, 95% CI -5.50 to -0.66) and
achieving better total effectiveness rate (OR 2.51, 95% CI 1.14
to 5.52) [12].
The risk of bias of the included four RCTs was analyzed in
Figure 3. Specifically, it was evaluated based on the published
manuscripts since none of the included RCTs registered their
protocol with any trial registry. Only one RCT applied proper
methods of random sequence generation (random number
table) as well as allocation concealment [12]. None of the
RCTs blinded participants or personnel. OneRCTconsidered
the use of blinding of outcome assessment as it used the
laboratory index as an outcome measure [44]. Only one RCT
specified dropouts (two in the treatment group and three in
the control group) [12]. All RCTs reported similar baseline
and none of them reported conflict of interest or funding
resources.
The findings from this review on clinical studies indicated
that DBKW achieved more benefits in relieving the global
symptoms of CP in four weeks, compared to antibiotic drugs
[15, 43, 44]. The add-on effects of DBKW to 𝛼-blocker were
also revealed as DBKW could reduce the NIH-CPSI score
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Figure 3: Risk of bias assessment in the four included RCTs.
within six weeks [12]. DBKW is considered safe as only
mild adverse events were reported, such as slight fatigue,
dizziness and postural hypotension [12]. However, some
methodological quality issues of the included RCTs were
identified. Only one out of four RCTs applied appropriate
randomization and allocation methods [12]. None of the
included studies applied placebo as a comparator, therefore,
the efficacy of DBKW could not be determined. Since the
blinding procedure was not incorporated in the included
studies, exaggerated estimation may occur [48]. Various
outcome measures were used in the included studies, rang-
ing from total effectiveness rate to laboratory tests, which
made data synthesis impossible. As NIH-CPSI is believed
to thoroughly reflect the current condition of CP from
different aspects (i.e., pain or discomfort, urination, impact
of symptoms, and quality of life) [49], it is suggested to use
it as a primary outcome measure to monitor intervention’s
effects on CP patients consistently. In addition, the follow-up
procedure is critical in the CP trials because CP is a
chronic disease and may undergo frequent recurrence [8].
However, none of the included RCTs involved a follow-up
evaluation. Thus, more high quality and properly designed
RCTs should be conducted in the future to systematically
assess the therapeutic effects ofDBKWon themanagement of
CP.
The findings from the current study are consistent with
those from another three recently published systematic
reviews [50–52]. All the reviews investigated the effects
and safety of oral intake of Chinese herbal medicine for
CP management. All of them indicated that Chinese herbs
could reduce the NIH-CPSI scores when compared to either
antibiotic/𝛼-blocker only or used as an adjunct therapy to
antibiotic/𝛼-blocker. They also claimed that oral administra-
tion of Chinese herbal medicine was safe for CP patients as
only mild adverse events were reported. In addition, similar
to our study, all the systematic reviews highlighted the poor
8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Multitargeting actions of Danggui Beimu KushenWan on chronic prostatitis.
quality of included studies and thus recommended rigorously
designed RCTs for future studies [50–52].
3.2. Multitargeting Actions of DBKW on CP in Experimental
Studies. Eight included experimental papers were conducted
by the same research team and focused on the mechanisms
of actions of DBKW for the management of CBP on rats
[53–60]. The team set up the CBP model by Escherichia coli
injection in the prostate of 60 Sprague-Dawley male rats.
Basic DBKW decoction was utilized for four weeks from
the 15th day of postsurgery whereas norfloxacin was used
in the control group. Details of the results are illustrated in
Figure 4. The five possible mechanisms of actions of DBKW
for CBP concluded in the experimental studies refer to anti-
inflammation [54–56], antibacteria [58], antioxidation [60],
sex hormone regulation [59], and immunoregulation [53, 57,
58].
DBKW contains more than one herb and therefore
it has multiple active compounds [61], such as Angelica
sinensis polysaccharides [62], ferulic acid [63], ligustilide
[64], matrine [10], oxymatrine [65], sophocarpine [66], and
peiminine [67]. Current research stated that combining active
compounds would produce additional or even synergistic
effects which are superior to a single compound, since
concurrent and selective interaction may occur with multiple
target proteins of a disease [68, 69]. The recent clinical
practice guideline recommended using multimodal therapy
(antibiotic with 𝛼-blocker, nonsteroidal anti-inflammatory
drug, or 5𝛼-reductase-inhibitors) to manage CP [6, 8].
However, long-term applications of those drugs may lead
to adverse events [70–73]. DBKW contains multitargeting
agentswhich could act onmore than one pathway of CP at the
same time [53–60] (Figure 4). Classic literature supported the
assertion thatDBKWmayhavemultiactions on the treatment
of difficult urination [11]. Compared to the conventional
management of CP, DBKWdeveloped less adverse events but
better treatment effects that may be due to its multiple natural
ingredients with diverse biological activities.
Evidence-Based Complementary and Alternative Medicine 9
4. Conclusion
DBKW has great potential in the treatment of CP evidenced
by the current studies described in this review. It is essential
to perform high-quality RCTs and network pharmacological
studies in future research of DBKW to investigate its clinical
effects and mechanisms of actions for CP.
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